

## **Finnish Clinic's New Elekta Radiation Therapy System Demonstrates Benefit of 3D Soft Tissue Visualization for Patients with Cancer**

*Image guided treatments jump 20 percent since Helsinki University Central Hospital acquires Elekta Axesse stereotactic system*

HELSINKI, Finland, September 20 – Helsinki University Central Hospital (HUCH) doubled its Image Guided Radiation Therapy (IGRT) capability with the acquisition of Elekta Axesse™, a system that provides 3D image guidance technology for conventional and stereotactic radiation therapy techniques. After eight months of use, HUCH has increased its Axesse caseload to as many as 30 patients each day for a variety of tumors in the lung, brain, head and neck and pelvis\*.

“We wanted to have a modern treatment system capable of 3D image guidance and delivery of complex radiation therapy techniques, such as VMAT,” says Mikko Tenhunen, Ph.D., chief physicist at HUCH. “In addition, we treat many small tumors here, so sophisticated field shaping and patient positioning and immobilization were critical. We compared several machines through the open call for tenders and Elekta Axesse obtained the best overall scores.”

Up to the point of the Axesse acquisition, HUCH clinicians relied on a single Varian IGRT system that provides 2D images, which is not ideal for soft tissue imaging. The Axesse system replaced a dated Varian Clinac® 600C machine.

“Especially for lung and pelvic tumors, 3D cone beam CT beats a pair of orthogonal 2D images in terms of image quality and ability to generate images using a low dose,” he adds. “Axesse has increased the number of image guided treatments by around 20 percent.”

In addition to 3D image guided localization at the time of treatment, Axesse provides ultra-conformal beam shaping with Beam Modulator™, the HexaPOD™ patient positioning system featuring six degrees (x,y,z, roll, pitch, yaw) of remote positional correction, non-invasive patient immobilization and advanced treatment planning with Monaco.

“Axesse has taken its place here at HUCH by clearly showing the value of 3D imaging over 2D imaging,” Dr. Tenhunen says.

Learn more about Elekta Axesse at [www.elekta.com/Axesse](http://www.elekta.com/Axesse).

*\* Approval of indications may vary between different countries. Additional regulatory clearances may be required in some markets.*

###

### **For further information, please contact:**

Stina Thorman, Vice President Corporate Communications, Elekta AB  
Tel: +46 8 587 254 37, email: [stina.thorman@elekta.com](mailto:stina.thorman@elekta.com)  
Time zone: CET: Central European

Michelle Lee, Director, Global Public Relations and Brand Management, Elekta  
Tel: +1 770-670-2447, email: [michelle.lee@elekta.com](mailto:michelle.lee@elekta.com)  
Time zone: EDT: Eastern Daylight

### **About Elekta**

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible. Today, Elekta solutions in

oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group. Elekta employs around 2,800 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTA. For more information about Elekta, please visit [www.elekta.com](http://www.elekta.com).